Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to ease joint pain for breast cancer patients on hormone therapy

NCT ID NCT07500038

Symptom relief Sponsor: Yuling CAO Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a culturally adapted program to help breast cancer patients manage joint and muscle pain caused by hormone therapy. 289 women on aromatase inhibitors received either the tailored program (health education, monitoring, and nursing guidance) or standard care. Researchers measured changes in joint function and how well the program was adopted in real-world clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Culturally Adapted EBP Program (behavioral intervention: health education, monitoring, nursing guidance)
What this could lead to
If it works, this could provide a practical, culturally sensitive way to help breast cancer patients manage joint pain and stiffness caused by hormone therapy.
What could go wrong
This is a completed implementation study, not a treatment trial. The program may not reduce symptoms significantly more than standard care, and results may not apply to all cultural groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

289 people

The number who actually took part.

Started

Dec 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically diagnosed Hormone Receptor Positive (HR+) primary breast cancer * Aged 18 years or older * Currently receiving Aromatase Inhibitors (AIs) endocrine therapy for at least 6 months * Self-reported Aromatase Inhibitor-induced Musculoskeletal Symptoms (AIMSS) * Possess basic communication skills, able to understand the research content, and voluntarily provide written informed consent * For the qualitative implementation evaluation, practitioners must be substantially involved in the clinical implementation of the AIMSS management program (e.g., patient recruitment, intervention delivery, digital tool guidance, or follow-up) * For the qualitative implementation evaluation, practitioners must provide informed consent for recorded interviews Exclusion Criteria: * History of bone fracture or related orthopedic surgery within the past 6 months * Previously diagnosed with inflammatory joint diseases (e.g., rheumatoid arthritis, ankylosing spondylitis) * Received other treatments for AIMSS not included in this study protocol within the past 1 month * Diagnosed with metastatic breast cancer or other primary malignant tumors * Concurrent serious dysfunction of vital organs (heart, brain, kidney, etc.) or uncontrolled infectious diseases * Presence of severe mental illness or cognitive impairment that prevents cooperation with the longitudinal study process

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aromatase inhibitor associated musculoskeletal symptoms (aimss) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aromatase inhibitor associated musculoskeletal symptoms (aimss) Breast neoplasms

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.